WallStreetZen

NASDAQ: SGRY
Surgery Partners Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for SGRY

Based on 4 analysts offering 12 month price targets for Surgery Partners Inc.
Min Forecast
$50.00+18.04%
Avg Forecast
$56.50+33.38%
Max Forecast
$73.00+72.33%

Should I buy or sell SGRY stock?

Based on 4 analysts offering ratings for Surgery Partners Inc.
Strong Buy
Strong Buy
2 analysts 50%
Buy
1 analysts 25%
Hold
1 analysts 25%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

SGRY stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
Barclays
Bottom 13%
13
Strong BuyInitiates Coverage On$73.00+72.33%2021-11-30
Stifel Nicolaus
Bottom 32%
32
Strong BuyUpgrades$51.00+20.40%2021-11-29
SVB Leerink
Top 36%
65
BuyMaintains$52.00+22.76%2021-11-03
Anonymous
JP Morgan
HoldInitiates Coverage On$50.00+18.04%2021-11-01
Cowen & Co.
Bottom 4%
4
HoldInitiates Coverage On$50.00+18.04%2021-09-10

1 of 1

Forecast return on equity

Is SGRY forecast to generate an efficient return?
Company
N/A
Industry
4.52%
Market
37.5%

Forecast return on assets

Is SGRY forecast to generate an efficient return on assets?
Company
N/A
Industry
0.08%

SGRY earnings per share forecast

What is SGRY's earnings per share in the next 2 years based on estimates from 2 analysts?
Avg 1 year Forecast
-$0.23-82.84%
Avg 2 year Forecast
$0.34-125.37%

SGRY revenue forecast

What is SGRY's revenue in the next 3 years based on estimates from 5 analysts?
Avg 1 year Forecast
$2.2B+3.49%
Avg 2 year Forecast
$2.5B+13.95%
Avg 3 year Forecast
$2.7B+25.85%
SGRY's revenue is forecast to grow at a rate of 7.88% per year, which is not exceptional
Forecast

SGRY revenue growth forecast

How is SGRY forecast to perform vs Medical Care Facilities companies and vs the US market?
Company
7.88%
Industry
6.87%
Market
10.08%
SGRY's revenues are forecast to grow faster (7.88% per year) than the US Medical Care Facilities industry average (6.87%)
Forecast
SGRY's revenues are forecast to grow slower (7.88% per year) than the US market average (10.08%)
Forecast

Surgery Partners Stock Forecast FAQ

Is Surgery Partners Stock a good buy in 2021, according to Wall Street analysts?

The consensus among 4 Wall Street analysts covering (NASDAQ: SGRY) stock is to Strong Buy SGRY stock.

Out of 4 analysts, 2 (50%) are recommending SGRY as a Strong Buy, 1 (25%) are recommending SGRY as a Buy, 1 (25%) are recommending SGRY as a Hold, 0 (0%) are recommending SGRY as a Sell, and 0 (0%) are recommending SGRY as a Strong Sell.

What is SGRY's earnings growth forecast for 2021-2022?

(NASDAQ: SGRY) Surgery Partners's forecast annual earnings growth rate of N/A is not forecast to beat the US Medical Care Facilities industry's average forecast earnings growth rate of 1.34%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 14.37%.

Surgery Partners's earnings in 2021 is -$85,900,000.On average, 2 Wall Street analysts forecast SGRY's earnings for 2021 to be $-18,960,446, with the lowest SGRY earnings forecast at $-22,257,914, and the highest SGRY earnings forecast at $-15,662,977.

In 2022, SGRY is forecast to generate $28,028,485 in earnings, with the lowest earnings forecast at $13,189,875 and the highest earnings forecast at $42,042,727.

What is SGRY's revenue growth forecast for 2021-2023?

(NASDAQ: SGRY) Surgery Partners's forecast annual revenue growth rate of 7.88% is forecast to beat the US Medical Care Facilities industry's average forecast revenue growth rate of 6.87%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.08%.

Surgery Partners's revenue in 2021 is $2,163,200,000.On average, 5 Wall Street analysts forecast SGRY's revenue for 2021 to be $184,553,063,545, with the lowest SGRY revenue forecast at $183,075,467,776, and the highest SGRY revenue forecast at $185,534,555,134. On average, 5 Wall Street analysts forecast SGRY's revenue for 2022 to be $203,207,668,914, with the lowest SGRY revenue forecast at $197,437,593,134, and the highest SGRY revenue forecast at $212,502,903,714.

In 2023, SGRY is forecast to generate $224,431,826,845 in revenue, with the lowest revenue forecast at $217,994,013,634 and the highest revenue forecast at $229,303,507,250.

What is SGRY's forecast return on assets (ROA) for 2021-2024?

(NASDAQ: SGRY) forecast ROA is N/A, which is lower than the forecast US Medical Care Facilities industry average of 0.08%.

What is SGRY's Price Target?

According to 4 Wall Street analysts that have issued a 1 year SGRY price target, the average SGRY price target is $56.50, with the highest SGRY stock price forecast at $73.00 and the lowest SGRY stock price forecast at $50.00.

On average, Wall Street analysts predict that Surgery Partners's share price could stay at $56.50 by Nov 30, 2022. The average Surgery Partners stock price prediction forecasts a potential downside of N/A from the current SGRY share price of $42.36.

What is SGRY's Earnings Per Share (EPS) forecast for 2021-2022?

(NASDAQ: SGRY) Surgery Partners's current Earnings Per Share (EPS) is -$1.34. On average, analysts forecast that SGRY's EPS will be $-0.23 for 2021, with the lowest EPS forecast at $-0.27, and the highest EPS forecast at $-0.19. In 2022, SGRY's EPS is forecast to hit $0.34 (min: $0.16, max: $0.51).

What is SGRY's forecast return on equity (ROE) for 2021-2024?

(NASDAQ: SGRY) forecast ROE is N/A, which is considered weak.
©2021 WallStreetZen
Company
AboutBlogPlansPrivacy PolicyTerms of ServiceCancellation & RefundsContact
Stocks
Stock ScreenerStock ForecastHighest Earnings StocksBest Dividend Paying StocksStatisticsTrending Stocks
Analysts
Top Performing Analysts
Social
TwitterYouTube
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.